endometriosis and glp 1 GLP-1 Meds & Endometriosis: What You NEED to Know GLP-1 Medications & Endometriosis: What

Tirzepatide (Mounjaro) is a dual GIP/GLP-1 receptor agonist currently licensed in the UK for type 2 diabetes only

This once weekly injection of (GLP-1) receptor agonist will be available in 0.5-mg and 1.0-mg doses, via a dedicated prefilled pen device

Pi-Sunyer et al, 2015)

Bioengineering & Translational Medicine

References Ian J Neeland, Jennifer Linge, Andreas L Birkenfeld, 2024, Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies pubmed.ncbi.nlm.nih.gov/38937282/ Allison B Reiss, Shelly Gulkarov, Raymond Lau, Stanislaw P Klek , Ankita Srivastava, Heather A Renna, Joshua De Leon, 2025, Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss Todd Miller, Stephanie Mull, Alan Albert Aragon, James Krieger, Brad Jon Schoenfeld, 2018, Resistance Training Combined With Diet Decreases Body Fat While Preserving Lean Mass Independent of Resting Metabolic Rate: A Randomized Trial Guidepoint Qsight, 2025, GLP-1 Medications Fuel Growth in Medical Aesthetics, with Weight Loss Accounting for 11% of Non-Surgical Spending in 2024 Tatiana Bido, 2024, New Report Tracks GLP-1s Impact on Plastic Surgery and Beauty Spending During Election Year Val Brickates Kennedy, 2024, Survey finds GLP-1 users more inclined to get aesthetic procedures AAFPRS Reveals New Statistics and Trends in Facial Plastic Surgery, 2025 Jessica Weiser, MD Ready to discover how Sofwave can transform your aesthetic practice